A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy

Pancreatic Cancer Clinical Trial

Official title:

A Phase I/II Clinical Study Using Pentamidine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Undergoing Standard Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00810953
• Other study ID #: OP-103-P
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: December 16, 2008
• Last updated: June 27, 2011
• Start date: January 2009
• Est. completion date: June 2011

Study information

• Verified date: June 2011
• Source: Oncozyme Pharma Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of pancreatic cancer metastasis in subjects receiving standard therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 2011
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically proven diagnosis of advanced pancreatic adenocarcinoma that is unresectable or metastatic. At least one uni-dimensionally measurable lesion (on spiral CT scan)

• 18 years of age or older

• ECOG performance status 0, 1 or 2

• Serum aspartate transaminase (AST) serum alanine transaminase (ALT) £ 2.5 x upper limit of normal (ULN), or AST and ALT £ 5 x ULN if liver function abnormalities are due to underlying malignancy

• Total serum bilirubin £ 2 x ULN

• lipase within normal limits (1.5x ULN)

• Absolute neutrophil count (ANC) = 1500/uL (1.5 x 109/L)

• Platelets = 100,000/uL

• Hemoglobin = 9.0 g/dL

• Serum creatinine £ 1.5 x ULN or calculated creatinine clearance = 50 ml/min

• CA19-9 level = 37 U/ml

• Normal ECG

• Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment

• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures

• Life expectancy, in the opinion of the investigator, > 3 months

Exclusion Criteria:

• BP < 100 (systolic)

• History of uncontrolled renal disease, pancreatitis, or diabetes mellitus

• Peripheral sensory neuropathy (> Grade 1, as per NCI CTCAE version 3.0)

• Concomitant therapy with other investigational agents or participation in another clinical trial within the previous 3 months.

• Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade = 2; atrial fibrillation of any grade; QTc interval >450 msec for males or >470 msec for females or uncontrolled intercurrent illness, e.g., unstable angina; severe coronary disease, ventricular arrhythmias, bradycardia <50 bpm

• Active uncontrolled bacterial infection

• Concurrent use of drugs that could prolong QT interval

• Concurrent use of nephrotoxic drugs, including aminoglycosides, ampho B, foscarnet, cidofovir

• Concurrent use of drugs that may be associated with pancreatitis

• Concurrent active cancer originating from a primary site other than pancreas or history of cancer < 3 years except for skin superficial bladder, uterus etc

• History of allergy or hypersensitivity to pentamidine

• Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to first dose of study medication.

• Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgement of the investigator, excess risk associated with trial participation of study drug administration, or which in the judgement of the investigator, would make the subject inappropriate for entry into this trial.

• On oral anticoagulants (LMWH is acceptable)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Pentamidine
two dose of 6 mg/kg with or without standard chemotherapy.

Locations

Country	Name	City	State
Canada	McGill University	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Oncozyme Pharma Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Any severe events, tumor marker CA19-9, and tumor size (CT scan)		6 months	Yes
Secondary	TDP		6 months	Yes